Phreesia (NYSE:PHR) Stock Rating Reaffirmed by JMP Securities

Phreesia (NYSE:PHR)‘s stock had its “market outperform” rating restated by analysts at JMP Securities in a research note issued to investors on Friday, Benzinga reports. They presently have a $30.00 price objective on the stock. JMP Securities’ price objective would suggest a potential upside of 16.69% from the company’s current price.

Several other equities research analysts have also issued reports on PHR. Truist Financial reissued a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Monday, July 1st. Stephens reissued an “overweight” rating and issued a $28.00 price objective on shares of Phreesia in a research note on Friday, May 31st. KeyCorp lowered their target price on shares of Phreesia from $27.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research note on Friday, May 31st. Finally, Canaccord Genuity Group decreased their price target on Phreesia from $37.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, May 31st. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.54.

Phreesia Trading Up 1.1 %

Shares of PHR stock opened at $25.71 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -11.85 and a beta of 0.93. Phreesia has a 1 year low of $12.05 and a 1 year high of $30.70. The firm has a fifty day moving average price of $23.03 and a 200-day moving average price of $22.89.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Thursday, May 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.16. Phreesia had a negative return on equity of 46.89% and a negative net margin of 31.87%. The business had revenue of $101.20 million during the quarter, compared to analyst estimates of $100.94 million. During the same quarter in the previous year, the company posted ($0.70) earnings per share. Phreesia’s revenue for the quarter was up 20.8% on a year-over-year basis. As a group, equities analysts predict that Phreesia will post -1.16 earnings per share for the current year.

Insider Transactions at Phreesia

In related news, General Counsel Allison C. Hoffman sold 14,110 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $26.03, for a total transaction of $367,283.30. Following the transaction, the general counsel now directly owns 121,003 shares in the company, valued at approximately $3,149,708.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Phreesia news, CEO Chaim Indig sold 2,644 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total value of $62,768.56. Following the sale, the chief executive officer now owns 1,219,361 shares in the company, valued at $28,947,630.14. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, General Counsel Allison C. Hoffman sold 14,110 shares of Phreesia stock in a transaction on Monday, August 26th. The stock was sold at an average price of $26.03, for a total value of $367,283.30. Following the sale, the general counsel now owns 121,003 shares of the company’s stock, valued at $3,149,708.09. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,337 shares of company stock worth $736,750. 5.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Phreesia by 4.4% during the 4th quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock valued at $107,148,000 after purchasing an additional 194,035 shares in the last quarter. Brown Advisory Inc. lifted its stake in Phreesia by 22.2% in the fourth quarter. Brown Advisory Inc. now owns 3,950,356 shares of the company’s stock worth $91,451,000 after acquiring an additional 716,374 shares during the period. Capital International Investors grew its holdings in Phreesia by 221.1% during the 1st quarter. Capital International Investors now owns 2,593,063 shares of the company’s stock worth $62,052,000 after acquiring an additional 1,785,463 shares in the last quarter. Franklin Resources Inc. grew its holdings in Phreesia by 15.0% during the 4th quarter. Franklin Resources Inc. now owns 1,484,663 shares of the company’s stock worth $34,370,000 after acquiring an additional 193,480 shares in the last quarter. Finally, Champlain Investment Partners LLC purchased a new position in Phreesia during the 1st quarter valued at about $29,941,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.